A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT02389985 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

30

Enrollment

INDUSTRY

Sponsor class

Stopped Company decision

Conditions

Ovarian Cancer

Interventions

DRUG: CRLX101
DRUG: Paclitaxel

Sponsor

NewLink Genetics Corporation